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The protective role of MLCP-
mediated ERM dephosphorylation 
in endotoxin-induced lung injury  
in vitro and in vivo
Anita Kovacs-Kasa1, Boris A. Gorshkov1, Kyung-Mi Kim1, Sanjiv Kumar1, Stephen M. Black2, 
David J. Fulton1, Christiana Dimitropoulou3, John D. Catravas3 & Alexander D. Verin1
The goal of this study was to investigate the role of MLC phosphatase (MLCP) in a LPS model of 
acute lung injury (ALI). We demonstrate that ectopic expression of a constitutively-active (C/A) MLCP 
regulatory subunit (MYPT1) attenuates the ability of LPS to increase endothelial (EC) permeability. 
Down-regulation of MYPT1 exacerbates LPS-induced expression of ICAM1 suggesting an anti-
inflammatory role of MLCP. To determine whether MLCP contributes to LPS-induced ALI in vivo, we 
utilized a nanoparticle DNA delivery method to specifically target lung EC. Expression of a C/A MYPT1 
reduced LPS-induced lung inflammation and vascular permeability. Further, increased expression of 
the CS1β (MLCP catalytic subunit) also reduced LPS-induced lung inflammation, whereas the inactive 
CS1β mutant increased vascular leak. We next examined the role of the cytoskeletal targets of MLCP, 
the ERM proteins (Ezrin/Radixin/Moesin), in mediating barrier dysfunction. LPS-induced increase in 
EC permeability was accompanied by PKC-mediated increase in ERM phosphorylation, which was 
more prominent in CS1β-depleted cells. Depletion of Moesin and Ezrin, but not Radixin attenuated 
LPS-induced increases in permeability. Further, delivery of a Moesin phospho-null mutant into murine 
lung endothelium attenuated LPS-induced lung inflammation and vascular leak suggesting that MLCP 
opposes LPS-induced ALI by mediating the dephosphorylation of Moesin and Ezrin.
Acute lung injury (ALI) is a critical hypoxemic respiratory failure characterized by vascular leak, alveolar capillary 
membrane damage, severe inflammation and pulmonary edema secondary to endothelial barrier dysfunction1. 
ALI has a high incidence among the US population and mortality rates remain excessive2. During ALI, bacterial 
sepsis is a major cause of mortality and bacterial toxins like LPS (lipopolysaccharide) and the endotoxins of 
Gram-negative bacteria3 contribute to inflammation and endothelial barrier dysfunction. LPS binds and activates 
TLR4 (Toll-like receptor 4) and promotes the activation of NFκ B and MAPK leading to the increased synthesis 
and release of inflammatory cytokines or type I interferon. LPS also stimulates PKC4 signaling and activates the 
small GTPase Rho5 resulting in actin cytoskeleton remodeling and the loss of endothelial barrier integrity.
Endothelial cells (EC) form a semi-permeable barrier between the circulating blood and the surrounding tis-
sues. Endothelial cells regulate the traffic of cells and fluids to the extravascular space through changes in perme-
ability. Loss of EC barrier function, a prominent feature of ALI, is tightly linked to agonist-induced cytoskeletal 
reorganization which disrupts cell-cell contacts, and promotes the formation of paracellular gaps6–8.
One of the major factors underlying increases in EC permeability is the actomyosin-driven contraction of 
EC. EC contraction is initiated by the reversible phosphorylation of the 20 kDa myosin regulatory light chain 
(MLC) at Ser19 and Thr18 amino acid residues, which is tightly linked to F-actin filament reorganization9. MLC 
phosphorylation is regulated by the activities of MLC kinases (MLCK and Rho-kinase) and MLC phosphatase 
(MLCP)10,11. The role of MLCK and Rho-kinase in the EC barrier dysfunction in vitro and in vivo is well doc-
umented12,13. However, the importance of MLCP which counteracts these mechanisms via dephosphorylation, 
in the regulation of the EC barrier remains largely unexplored. MLCP is a type-1 protein phosphatase (PP1), 
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composed of the PP1 catalytic subunit (CS1β formerly CS1δ ) and two non-catalytic subunits, the 20 kDa small 
regulatory subunit (M20) and a 110–130 kDa regulatory subunit, called myosin phosphatase targeting subunit 1 
(MYPT1)14,15. We have previously shown that MLCP-mediated signaling plays an important role in EC barrier 
strengthening induced by extracellular purines in vitro16–18. However, its role in the regulation of lung vascular 
permeability in an LPS model of ALI is unknown.
We and other groups have previously reported that Ezrin/Radixin/Moesin (ERM) proteins are substrates for 
MLCP18–20. ERM proteins are members of the protein 4.1 superfamily and are characterized by a plasma mem-
brane associated FERM domain at the N-terminus and an F-actin binding C-terminal ERM association domain21. 
ERMs function as linkers between the plasma membrane and the actin cytoskeleton, and are involved in many 
crucial cellular functions such as cell adhesion, membrane ruffling and microvilli formation21,22. ERM proteins 
can be phosphorylated on several Ser/Thr and Tyr residues23,24 and the most-studied sites are the conserved Thr 
residues at the C terminal (Thr558 in Moesin, Thr576 in Ezrin and Thr564 in Radixin). The phosphorylation 
of these Thr residues on the C terminus activates ERMs by reducing the affinity between the transmembrane 
N-terminus and the ERM association domain. Activated ERMs are able to bind their target proteins (F-actin or 
protein kinases)25.
While we and others have recently shown that the phosphorylation/dephosphorylation of ERMs is involved in 
EC cytoskeletal regulation in various permeability models in vitro20,26 their role in the regulation of LPS-induced 
EC permeability has not been reported.
In this study our goal was to define the role of MLCP and its cytoskeletal targets, the ERM proteins, in the LPS 
model of lung injury in vitro and in vivo. For the first time, we demonstrate that MLCP is involved in vascular 
endothelial barrier protection against LPS-induced EC barrier disruption in vitro and in vivo in a murine model 
of ALI. We show that LPS increases ERM and MLC phosphorylation via the activation of different pathways. 
Moesin and Ezrin, but not Radixin, are directly involved in LPS-induced EC barrier disruption in vitro. Further, 
introduction of phospho-null Moesin mutant into the mouse lung significantly attenuates LPS-induced lung 
inflammation and vascular leak suggesting that Moesin dephosphorylation may protect against lung injury in a 
LPS-mediated murine model of ALI in vivo.
Results
MLCP is involved in endothelial barrier protection against LPS-induced lung vascular injury 
in vitro and in murine model of ALI. Our group has previously shown that MLCP has a critical role in 
EC barrier strengthening induced by extracellular purines16–18 and in protection against thrombin-induced EC 
barrier compromise in vitro18. To examine the role of MLCP in EC barrier compromise in a cell culture model we 
first analyzed LPS-induced permeability changes to identify the effective dose of LPS in human pulmonary artery 
endothelial cells (HPAEC). We show that LPS concentrations in the range of 0.2–1 μ g/ml induced comparable 
decreases in TER with maximal effect at 6–8 hours of treatment (Fig. 1A). Consequently, we used the lowest con-
centration (0.2 μ g/ml) in all subsequent experiments. To determine whether MLCP activity has a protective role 
in the LPS model of EC barrier compromise, we performed ECIS experiments with EC overexpressing the C/A 
truncated MYPT1 (C/A MYPT1 1–300). HPAEC were transduced with LacZ (control) or with C/A MYPT1-myc 
adenovirus. 24 hours after infection, HPAEC were treated with LPS or vehicle-control, and TER was monitored 
for 12 hours. We found that the overexpression of C/A MYPT1 attenuates LPS-mediated decrease in HPAEC 
barrier function (Fig. 1B). These results are consistent with our previously published observations indicating that 
depletion of MYPT1 significantly attenuated HPAEC barrier enhancement induced by extracellular purines (ref. 
17, 18). To further define the role of MLCP in LPS-induced ALI in vitro, we examined the effect of MYPT1 
depletion on ICAM1 expression in LPS-treated HPAEC (Fig. 1C–E). Our results demonstrate that LPS increases 
ICAM1 expression levels after 4 hours in a time-dependent manner in non-targeting siRNA-transfected control 
cells (Fig. 1C). MYPT1 depletion exacerbated the effect of LPS (Fig. 1D) strongly supporting the direct anti-in-
flammatory role of MLCP in this LPS model of endothelial injury.
To evaluate whether MLCP activity has a barrier-protective and anti-inflammatory role in LPS-induced vascu-
lar barrier injury in vivo, we utilized a LPS murine model of ALI in conjunction with a lung-targeted gene delivery 
method which we have recently developed27. In this approach, commercial (Polyplus) cationic polymer jetPEI 
(polyethyleneimine) transfection reagent forms a complex with the DNA of interest that specifically targets the 
lungs with preferential localization to the endothelium27. Utilizing this approach, plasmid encoding C/A MYPT1 
1–300 or vector control (empty pcDNA 3.1) complexed with JetPEI was introduced intravenously (i.v.). Three 
days (72 hrs) later, LPS or vehicle was instilled intratracheally (i.t.). Capillary leak was estimated using Evans Blue 
Dye-conjugated albumin, and lung inflammation was evaluated by MPO staining as described in Materials and 
Methods. The efficiency of the in vivo gene delivery was confirmed by immunoblotting of lung homogenates with 
c-myc-specific antibody. Results in Fig. 2 demonstrate that overexpression of C/A MYPT1 significantly attenuates 
LPS-mediated lung vascular permeability increase (Fig. 2A). Furthermore, ectopic expression of C/A MYPT1 
dramatically decreased lung inflammation caused by LPS (Fig. 2B). Therefore, our results indicate that MLCP 
plays an anti-inflammatory and barrier-protective role against LPS-induced ALI in mice.
To further confirm our findings, we introduced expression plasmids containing either wild type CS1β (C/A) or 
the dominant negative (D/N) mutant CS1β (MLCP catalytic subunit) into mouse lungs using the JetPEI-assisted 
delivery approach. Our results demonstrate that wild type CS1β significantly reduces LPS-induced inflammatory 
processes in the mouse lung, as inferred from a reduction of protein content in BALF (Fig. 2C). Conversely, intro-
duction of the D/N CS1β mutant significantly increases vascular leak (Fig. 2D). Collectively, our present results 
strongly implicate the involvement of MLCP activity in EC barrier strengthening in vitro and in a murine model 
of LPS-induced ALI.
www.nature.com/scientificreports/
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LPS-induced increases in MLC and ERM phosphorylation involves activation of different signaling 
pathways. We have previously shown that MLCP substrates, MLC and ERM proteins, are involved in EC 
barrier regulation in various endothelial permeability models18,20,28. To clarify the involvement of LPS in MLC 
and ERM phosphorylation and find a link between MLC and ERM phosphorylation level changes we analyzed 
the levels of di-phospho-MLC and phospho-ERM in HPAEC. ERM and MLC phosphorylation in LPS-challenged 
endothelial cells was analyzed by immunoblotting at discrete time points (0, 1, 2, 4, 6, 8 hours) utilizing an 
anti-di-phospho MLC antibody (Thr 18/Ser19) and a phospho-specific ERM antibody (phospho-Ezrin Thr567/
Radixin Thr564/Moesin Thr558). Our data demonstrate that LPS induced a gradual increase in Thr phosphoryl-
ation of ERMs which correlated with LPS-induced permeability changes (Fig. 1A). In contrast, the increase in 
MLC phosphorylation (maximum at 2–4 hours) preceded the maximal LPS-mediated EC barrier compromise 
(Fig. 1A). This data suggest that, similar to the thrombin model29, the increase in MLC phosphorylation may be 
involved in the initiation of LPS-caused EC barrier compromise, whereas increase in ERM phosphorylation is 
important for the development of the maximal response. Therefore, LPS-induced increases in MLC and ERM 
phosphorylation require activation of different signaling pathways.
Figure 1. (A) Effect of different concentrations of LPS on TER in HPAEC. HPAEC were plated on gold 
microelectrodes in ECIS arrays (8W10E+ ). Once a constant resistance was reached, the cells were treated with 
either vehicle (0.1% DMSO) or different concentrations of LPS of (0.2, 0.4 or 1 μ g/ml) at indicated time, and 
TER was monitored for 24 hours. (B) Effect of MLCP activation on LPS-induced permeability increase. HPAEC 
were transduced with LacZ (control) or C/A MYPT1 adenovirus (20 MOI), and 24 hours later cells were plated 
on ECIS arrays (8W10E+ ). After reaching a constant resistance, cells were treated with either vehicle (0.1% 
DMSO) or LPS (0.2 μ g/ml) at indicated time and TER was monitored for 12 hours. Normalized resistance was 
calculated and plotted as a function of time. The overexpression of C/A MYPT1 was detected by Western blot 
(inset). ***P < 0.0001 vs. control; ###P < 0.0001 vs. C/A MYPT1/LPS. (C–E) Effect of MLCP down-regulation on 
LPS-induced ICAM1 expression. (C,D) Representative immunoblots of MYPT1 and ICAM1 showing ICAM1 
and MYPT1 expression. HPAEC were transfected with non-targeting siRNA (C) or MYPT1 specific siRNA 
(D). After 72 hours incubation, cells were treated with LPS (0.2 μ g/ml) for different time periods (0, 1, 2, 4, 6, 8, 
16 hours) and western blot analysis was performed. (E) Bar graph showing changes in protein levels of ICAM1 
quantified with scanning densitometry. Results are expressed as Mean ± SEM (n = 5 experiments). *P < 0.05, 
**P < 0.01 vs. non-siRNA transfected control; ##P < 0.01, vs. MYPT1-siRNA transfected control; $$P < 0.01, 
$$$P < 0.0001 non-siRNA/LPS vs. MYPT1-siRNA/LPS.
www.nature.com/scientificreports/
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To confirm that ERM are substrates of MLCP in HPAEC, we depleted the MLCP catalytic subunit, CS1β , 
utilizing a siRNA approach. HPAEC were transfected with a specific-CS1β siRNA or a scrambled siRNA control, 
then treated with LPS for the indicated time periods, and the level of ERM phosphorylation was determined by 
immunoblotting with a phospho ERM antibody, as described in “Materials and Methods”. Our results show that 
Figure 2. C/A MYPT1 expression attenuates LPS-induced lung inflammation in vivo. (A) A plasmid (40 μ g) 
encoding C/A MYPT1 (1–300) fragment or empty pcDNA 3.1 (40 μ g) was complexed with JetPEI and injected 
via a tail vein. LPS (1 mg/kg) was administered intratracheally (i.t.) 72 h later, then capillary leak was evaluated 
using Evans blue dye. Bar graph shows EBD (μ g/g) in lung tissue, ***P < 0.0001 pcDNA 3.1 vs. pcDNA 3.1/LPS;  
#P > 0.05 control LPS vs. C/A MYPT1/LPS. Western blot shows the expression level of C/A MYPT1 in mouse 
lungs injected with pcDNA3.1 control plasmid or with C/A MYPT expression plasmid using anti-c-myc  
antibody and actin as a loading control. (B) MPO staining of control, LPS, C/A MYPT1/LPS mouse lung 
samples. Plasmid encoding wild type (C) or mutant (D) CS1β was complexed with jetPEI then injected i.v., 
and 72 hours later LPS (1 mg/kg) was administered i.t. Protein concentration in BALF (C) and EBD (D) 
were evaluated. Western blot shows the expression level of CS1β in mouse lungs. The samples from (C) and 
(D) derive from the same experiment and that gels/blots were processed in parallel. Results are expressed as 
Mean ± SEM (n = 5 experiments). *P < 0.05 control vs. mutant CS1β , ***P < 0.0001 control vs. LPS; #P < 0.05, 
##P < 0.01, LPS vs. CS1β /LPS.
www.nature.com/scientificreports/
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Figure 4. MLCP activity plays an important role in ERM dephosphorylation. (A,B) Representative 
immunoblots showing the levels of pERM and CS1β expression. HPAEC monolayers were transfected using non-
targeting siRNA (A) or CS1β specific siRNA (B). After 72 hours, cells were treated with LPS (0.2 μ g/ml) for different 
time periods and western blot analysis was performed using anti phospho-ERM and CS1β antibodies. The samples 
from (A) and (B) derive from the same experiment and that gels/blots were processed in parallel. (C) Bar graph 
shows the changes in phospho-ERM content quantified with scanning densitometry. Results are expressed as 
Mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.0001 vs. non-siRNA transfected control; #P < 0.05, ##P < 0.01, 
###P < 0.0001 vs. CS1β -siRNA transfected control; $$$P < 0.0001 non-siRNA/LPS vs. CS1β -siRNA/LPS.
Figure 3. LPS induces phosphorylation of ERM and MLC in a time-dependent manner. (A) Western blot 
analysis of the phosphorylation level of ERM proteins and phospho-MLC in HPAEC. Actin served as a loading 
control. HPAEC were treated with LPS (0.2 μ g/ml) for the indicated time periods. (B/C) Bar graph shows the 
changes in protein levels of phospho-ERM and phospho-MLC quantified with scanning densitometry. Results 
are expressed as Mean ± SEM (n = 4 experiments). *P < 0.05, **P < 0.01, ***P < 0.0001 vs. control.
www.nature.com/scientificreports/
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depletion of CS1β significantly increased ERM phosphorylation in control and LPS-treated HPAEC, compared 
to the scrambled siRNA transfected cells (Fig. 4A–C).
To evaluate the kinases involved in LPS-induced MLC and ERM phosphorylation, we used pharmaco-
logical approach. We applied Rho-kinase inhibitor, Y-27632 (10 μ Μ ), PKC-inhibitor, Ro-31–7459 (10 μ Μ ) 
or DMSO-control (0.1%) one hour before adding LPS (0.2 μ g/ml) for six hours. Inhibition of PKC, but not 
Rho-kinase, abolishes LPS-induced ERM phosphorylation in human EC. In contrast, Rho-kinase, but not PKC, 
is involved in LPS-induced MLC phosphorylation (Fig. 5A). Therefore, we identified PKC, but not Rho kinase as 
a major kinase involved in ERM phosphorylation in LPS-challenged EC. In contrast, the major kinase responsible 
for MLC phosphorylation is Rho kinase, as expected.
The role of ERM proteins in LPS-induced EC barrier dysfunction. Our recently published results 
demonstrate that ERM proteins play important, but different roles in the thrombin-induced EC barrier dys-
function: Moesin, and to a lesser extent Ezrin promote barrier dysfunction, and Radixin opposes it28. However, 
we have also shown that individual ERM protein depletion significantly attenuates the EC permeability increase 
induced by the microtubule disruptor, 2-methoxyestradiol (2ME)20. Further, HPAEC monolayers overexpress-
ing phospho-null ERM mutants, exhibit less attenuation of 2ME-induced hyper-permeability, in response to 
PKC inhibition, implicating the phosphorylation of all ERMs in EC barrier dysfunction20. Collectively, this data 
suggest that involvement of ERM proteins in EC barrier regulation is likely to be agonist-specific. To examine 
the functional role of individual ERM proteins in LPS-induced EC barrier dysfunction, TER was used to detect 
permeability changes in Moesin-, Ezrin- or Radixin-depleted HPAEC. Non-targeting siRNA transfected cells 
were used as controls. The efficiency of the depletion of each protein was confirmed by immunoblotting. Our 
data demonstrates that Moesin (Fig. 6A) and Ezrin (Fig. 6B) depletion significantly attenuated the effect of LPS 
on TER, while depletion of Radixin slightly decreased basal TER, but did not significantly alter the LPS response 
(Fig. 6C). Therefore, our data demonstrates that ERM proteins have different roles in LPS-induced EC barrier 
compromise and confirms that the involvement of these proteins in EC barrier regulation may be agonist-specific.
Figure 5. LPS-induced phosphorylation of ERM and MLC involves different signaling. HPAEC were 
pretreated with ether a Rho-kinase (Y-27632, 10 μ Μ ), or a pan PKC (Ro-31-7459, 10 μ Μ ) inhibitor, or with 
DMSO (0.1%), one hour before adding LPS (0.2 μ g/ml). At designated time, cells were harvested and analyzed 
by immunoblotting. (A) Representative immunoblots show the phosphorylation levels of phospho-ERM and 
phospho-MLC. (B/C) Bar graphs show the changes in the levels of phospho-ERM and phospho MLC quantified 
with scanning densitometry. Results are expressed as Mean ± SEM (n = 5 experiments). **P < 0.01, vs. DMSO 
control; #P < 0.05, ###P < 0.0001 vs. DMSO control/LPS.
www.nature.com/scientificreports/
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The role of Moesin phosphorylation in LPS-induced vascular barrier dysfunction in vivo. We 
have previously shown that Moesin is the predominant ERM protein in HPAEC28. It is involved in EC barrier 
compromise in several permeability models including LPS-caused EC barrier dysfunction in vitro20,28 (Fig. 3A). 
Moesin is activated by phosphorylation at Thr55825. To assess the role of Moesin phosphorylation in vascular bar-
rier regulation in vivo we generated a phospho-null Moesin mutant (Thr558 to Ala18) and utilized an in vivo LPS 
murine model of ALI in conjunction with jetPEI delivery method, as we have recently described27. Mammalian 
expression plasmids coding either phospho-null Moesin mutant in pcDNA 3.1 or a control empty pcDNA 3.1 
plasmid were injected into mice via a tail vein27. The overexpression of phospho-null Moesin mutant significantly 
decreased lung permeability inferred from EBD extravasation (Fig. 7A) and also decreased the protein level in 
BALF (Fig. 7B) from mouse lungs treated with LPS, indicative of lung inflammation. This data demonstrated 
for the first time that Moesin phosphorylation is involved in LPS-induced ALI in vivo, therefore supporting 
barrier-protective role of MLCP (which dephosphorylate Moesin) in vitro and in vivo.
Discussion
Endotoxin lipopolysaccharide (LPS), a constituent of the cell wall of Gram-negative bacteria, is a potent 
pro-inflammatory agent that directly disrupts EC barrier function in both macro- and microvascular EC5,30 
LPS-mediated murine lung injury, is a disease model that shares many characteristics of sepsis-induced ALI/
ARDS in humans. Specifically, the injury elicited is characterized by neutrophil infiltration into the lung in 
association with increased pro-inflammatory mediators including nuclear factor (NF)-κ B which leads to the 
up-regulation of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α , IL-6, IL-8, the up-regulation 
of ROS and RNS generators (NADPH oxidase, iNOS), increased formation of protein-rich alveolar fluid (edema), 
structural damage to the alveolo-capillary membrane and compromised lung function31,32.
It has been well established that edemagenic agents like thrombin or histamine induce cytoskeletal rearrange-
ment via MLCK, PKC and activation of RhoA leading to the formation of paracellular gaps and the loss of EC 
barrier integrity7,33,34. The precise mechanisms by which LPS-induced signaling leads to EC barrier disruption are 
not yet fully clarified. However, it is clear that LPS acts through the activation of cell surface TLR4 which leads to 
reorganization of the actin cytoskeleton and increased EC permeability (reviewed in ref. 8). Similar to thrombin, 
LPS promotes cytoskeletal changes that are dependent, at least in part, on the activation of PKC and Rho signaling 
Figure 6. Moesin and Ezrin, but not Radixin depletion significantly attenuates effect of LPS on TER. 
HPAEC was plated on small gold electrodes in ECIS chamber and were transfected with siRNAs (50 nM) to 
deplete (A) Moesin, (B) Ezrin, (C) Radixin, and using SiPort-based delivery. Three days after transfection, TER 
was measured. After stabilization for 1 hour, cells were challenged with LPS (0.2 μ g/ml), and the change in TER 
was recorded for 8–20 hours. Non-targeting RNA (Non-siRNA) was used as a control. Results are expressed as 
Mean ± SEM, n = 3 experiments. Normalized resistance was calculated and plotted as a function of time. Insets. 
Representative immunoblots showing the level of individual ERM protein depletion. ***P < 0.0001 vs. control; 
###P < 0.0001 vs. Moesin or Ezrin or Radixin- siRNA/LPS.
www.nature.com/scientificreports/
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pathways35–37. Rho/Rho-kinase activation leads to increased MLC phosphorylation and EC contraction. Rho-kinase 
phosphorylates MLC directly on Ser19 and (or) indirectly via increased phosphorylation of the inhibitory site 
of MYPT1 leading to MLCP inhibition and a subsequent increase in MLC phosphorylation at Thr18/Ser198,38. 
PKC activation can also lead to increased MLC phosphorylation via activation of the MLCP inhibitor, CPI-17 
(PKC potentiated inhibitory protein of 17 kDa) or activation of the Rho pathway via PKC-mediated inhibition of 
the Rho inhibitor, GDI-134,39,40. However, the latter signaling pathways have not been defined in a LPS permeabil-
ity model. Other putative cytoskeletal targets of PKC include the actin binding proteins caldesmon and the ERM 
proteins (reviewed in ref. 8), however, their role in LPS-induced lung injury is also unknown.
Pathways that can protect the endothelial barrier against LPS-induced lung injury are far less understood. 
Our recently published data have demonstrated barrier-protective effects of HSP-90 inhibitors, DDAH II 
(dimethylaminohydrolase II) overexpression, microtubule stabilization, extracellular β -NAD (β -nicotinamide 
adenine dinucleotide) and extracellular purines, ATP and adenosine27,35,41–44. We have previously shown that 
purine-induced EC barrier strengthening is tightly linked to activation of MLCP and MLCP is involved EC bar-
rier protection against thrombin-induced EC barrier compromise in vitro16–18. However, the role of MLCP in 
LPS-induced lung injury in vitro and in vivo has not been described and was the aim of the current study.
We demonstrated that the ectopic expression of a C/A MLCP regulatory subunit (truncated MYPT1, 
1–300) significantly attenuates the LPS-induced decreases in TER reflecting EC barrier protection. In contrast, 
down-regulation of MYPT1 leads to exacerbation of LPS-induced expression of ICAM-1 suggestive of a direct 
anti-inflammatory function of MLCP. To further define the role of MLCP in LPS-induced ALI in vivo, we utilized 
a nanoparticle DNA delivery method which we recently developed27 to specifically target lung EC. Using this 
method, we demonstrated that ectopic expression of C/A MYPT1 reduces lung inflammation (MPO staining) 
and attenuates LPS-induced vascular permeability (Evans Blue Dye albumin (EBA) extravasation into the lung). 
Consistent with these results, delivery of plasmids encoding the wild type CS1β (MLCP catalytic subunit) signif-
icantly reduced LPS-induced lung inflammation as determined by the reduction of protein content in broncho-
alveolar lavage fluid (BALF). Conversely, the in vivo transfection of a catalytically inactive (D/N) CS1β mutant 
increases vascular leak. Collectively, these data convincingly demonstrate for the first time that MLCP directly 
provides EC barrier protection against LPS-induced EC barrier disruption in vitro and LPS-induced vascular leak 
in vivo. In addition, they support an anti-inflammatory role of MLCP in vitro and in vivo.
MLC is the classical substrate for MLCP. MLCP-mediated MLC dephosphorylation is primarily regulated by 
MYPT1 binding to myosin14,15,45. However, more recent studies indicate that additional cytoskeletal proteins may 
be targets for MLCP and suggest that MLCP may have a broader multidirectional involvement in the control of 
EC cytoskeleton and permeability12,46,47.
ERM (Ezrin/Radixin/Moesin) proteins are unconventional MLCP cytoskeletal substrates19,48 ERM proteins 
act both as linkers between the actin cytoskeleton and plasma membrane, and as signal transducers in responses 
involving cytoskeletal remodeling49–51. In the unphosphorylated form, ERM proteins exist in auto-inhibited 
conformation. Phosphorylation induces and stabilizes the unfolded active conformation of ERMs, allowing 
them to simultaneously bind to membrane and actin filaments51,52. MYPT1 can bind to ERM proteins and facil-
itates MLCP-dependent ERM dephosphorylation19. Importantly, we and others have shown that ERM proteins 
are involved in EC barrier regulation20,26,28,53, however, their role in LPS-induced EC barrier compromise was 
unknown. Our data demonstrate that LPS-induced ERM phosphorylation occurs in parallel with the reduction 
in TER. In contrast, LPS-induced MLC phosphorylation is transient with a nadir at 2–4 hrs, which precedes 
maximal changes in permeability. These data suggest that LPS-induced MLC phosphorylation is involved in 
the initiation of the contractile response and mediates permeability increases, whereas ERM phosphorylation 
Figure 7. Moesin phosphorylation plays an essential role in LPS-induced lung injury in vivo. PcDNA3.1 
plasmids (40 μ g) encoding empty vector (control) or unphosphorylatable Moesin mutant were complexed 
with JetPEI transfection reagent. Three days later, LPS (1 mg/kg) was injected i.t. (A) Bar graph shows Evans 
Blue dye extravasation, reflecting capillary leak. Western blot of lung homogenates stained for HA-tagged 
Moesin-mutant. (B) Bar graph shows protein levels in BALF (an index of lung inflammation and capillary leak). 
*P < 0.05, ***P < 0.0001 vs. control, ##P < 0.01, ###P < 0.0001 vs. control/LPS.
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may be important for the magnitude and/or duration of permeability increases. Our data also demonstrate that 
LPS-induced increases in ERM phosphorylation are more prominent in CS1β -depleted cells and confirm that 
ERMs are cytoskeletal targets for MLCP in EC.
ERM proteins are phosphorylated at conserved Thr residues on the C-terminus (Thr 558 for Moesin, Thr567 
for Ezrin and Thr564 for Radixin). The established literature indicate that multiple kinases are involved in the 
phosphorylation of ERMs in different cell types and in response to various stimuli. Initially Rho-kinase and PKC 
were the only kinases reported to phosphorylate ERM54–56. Lately, several other kinases have been identified that 
phosphorylate ERMs in different cell types57. Importantly, studies on lymphocytes demonstrate that the kinase(s) 
responsible for ERM phosphorylation may be cell-specific57.
According to a recent publications, ERM phosphorylation in EC is dependent on PKC, p38, and Rho-kinase 
either alone or in combination26,53. We have recently shown that thrombin-induced EC barrier dysfunction is 
accompanied by PKC-mediated ERM phosphorylation28. In addition, we have demonstrated that the microtubule 
disruptor, 2-methoxyestradiol (2ME), increases ERM phosphorylation in a p38/PKC-dependent fashion. The 
activation of p38 appears to occur upstream from the activation of PKC20. In contrast, TNFα -induced increases 
in ERM phosphorylation and EC barrier dysfunction likely involves parallel activation of p38 and PKC-mediated 
signaling53. Our data demonstrate that LPS-induced ERM phosphorylation is PKC, but not Rho-kinase depend-
ent. At the same time we have demonstrated that LPS-induced MLC phosphorylation is Rho-kinase, but not 
PKC-dependent. These data indicate that LPS-induced ERM and MLC phosphorylation require the activation of 
different signaling pathways and support the hypothesis that MLC and ERM phosphorylation may be involved in 
different phases of LPS-induced EC permeability responses.
We and others have recently demonstrated that despite structural similarity among the ERM proteins, their 
individual roles in EC barrier function may vary and the degree of involvement may be agonist-specific26,28. These 
observations highlight the critical need to examine the role of individual ERM proteins in LPS-induced EC bar-
rier disruption. Using short interfering RNA to specifically deplete Ezrin, Moesin and Radixin in EC, we demon-
strated that depletion of Moesin and Ezrin significantly attenuates LPS-induced decrease in TER. In contrast, 
depletion of Radixin, but not Moesin and Ezrin modestly decreases baseline TER of unstimulated EC monolayers 
and has no significant effect on LPS-induced increases in permeability. The origin of the functional differences 
between highly homologous ERM proteins are not entirely clear, but most likely arises from differences in the 
interactions with partnering regulatory proteins. For example, Moesin and Ezrin differentially bind to L-selectin 
in lymphocytes58; Radixin, but not Ezrin or Moesin bind to the integral membrane hyaluronan receptor, layilin59. 
Further, we have recently shown that ERM proteins have a different binding affinity toward the subunits of MLCP, 
CS1β and MYPT1. Moesin and to a lesser extent Ezrin, but not Radixin can be detected in CS1β immunoprecip-
itates. In contrast, Radixin, but not Ezrin or Moesin co-immunoprecipitates with MYPT1 in COS7 cells18. These 
differences in the binding capacities of ERM proteins for MLCP subunits may contribute to the different func-
tional roles of ERM proteins in EC barrier regulation. However, the exact role of differential ERM-MLCP binding 
both at baseline and following LPS-stimulation remains to be determined.
Using phosphorylation-deficient ERM mutants that were ectopically expressed in EC, we have recently 
demonstrated a direct role of ERM phosphorylation in the loss of EC barrier integrity induced by the micro-
tubule inhibitor, 2ME, in vitro20. To evaluate the role of ERM phosphorylation in LPS-induced vascular barrier 
dysfunction in vivo we delivered an expression plasmid encoding a phospho-null Moesin mutant into murine 
lung using a nanoparticle based DNA delivery method27. Our data demonstrate that ectopic expression of the 
phosphorylation-deficient Moesin significantly attenuates LPS-induced lung inflammation and vascular leak sup-
porting a regulatory role of changes in Moesin phosphorylation in mediating changes in vascular barrier perme-
ability in response to LPS. To the best of our knowledge, this is the first report directly showing a role of Moesin 
phosphorylation/dephosphorylation in the regulation of lung vascular barrier function in vivo.
Collectively, our data demonstrated that MLCP opposes LPS-induced lung injury in vitro and in vivo, at least 
in part, via dephosphorylation of its cytoskeletal targets, the ERM proteins.
Materials and Methods
Materials. All chemicals were purchased from Sigma-Aldrich (St. Louis), unless otherwise indicated. LPS 
is E. coli serotype 0127:B8, endotoxin level 3,000,000 endotoxin units/mg. Antibodies were from Cell Signaling 
Technology, Inc. (Danvers, MA): phospho-Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558) rabbit monoclonal 
antibody, MYPT1 rabbit monoclonal antibody, GAPDH rabbit monoclonal antibody, p-Myosin Light Chain 2 
(Thr18/Ser19) rabbit polyclonal antibody, Ezrin, Radixin, Moesin rabbit monoclonal antibodies. Jet-PEI reagent 
was obtained from Polyplus-transfection Inc. (New York, NY). Myeloperoxidase (MPO) assay kit was purchased 
from Dako North America, Inc. (Carpinteria, CA). The Rho kinase inhibitor Y-27632 and the PKC inhibitor 
Ro-31-7549 were purchased from Calbiochem (San Diego, CA). ECIS arrays (8W10E+ ) were from Applied 
BioPhysics (Troy, NY). Transfection plasmids were generated in our laboratory as we have previously described18. 
The phospho-null Moesin mutant was generated by Stratagene (San Diego, CA) using our wild type construct as 
a template. Plasmid containing C/A MYPT1 (amino acids 1–300), which was generously provided by Dr. M. Eto 
(Thomas Jefferson University, Philadelphia, PA), was used as a template for subcloning of C/A MYPT1 (1–300) 
into an adenoviral vector. Construction of adenovirus containing C/A MYPT1 was performed in the laboratory 
of Dr. D. Fulton (Augusta University, Augusta, GA) according to published protocols (Qian et al., 2009).
Ethical approval of the study protocol. The study protocol was approved by the Animal Care and Use 
Committee of Augusta University (Augusta, GA). The care and treatment of animals was undertaken according 
to guidelines set by the National Institutes of Health (Bethesda, MD).
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Cell Culture. Human pulmonary artery endothelial cells (HPAEC) obtained from Lonza Group Ltd. 
(Walkersville, MD) were propagated in culture medium EGM-2-MV (Lonza) supplemented with 5% (v/v) fetal 
bovine serum (FBS; HyClone, Waltham, MA) and used at passages 3–7. All cells were maintained at 37 °C in a 
humidified atmosphere of 5% CO2.
Small interfering RNA-mediated depletion. HPAEC were transfected with 50 nM of Ezrin, Radixin, 
Moesin, CS1β , or MYPT1 small interfering RNA (siRNA) (GE Dharmacon, Lafayette, CO) using SiPort (Thermo 
Fisher Scientific Ambion, Grand Island, NY) transfection reagent according to the manufacturer’s instructions. 
Non-targeting siRNA was used as a negative control (Santa Cruz Biotechnology, Santa Cruz, CA).
Western blot analysis. Immunoblotting was performed as we have described previously18,60. Membranes 
were probed with antibodies against MYPT1, phospho-ERM, di-phospho-MLC, CS1β , Ezrin, Radixin, and 
Moesin. Re-probing with anti-β -actin or GAPDH was used to normalize protein loading.
Measurements of transendothelial electrical resistance of EC monolayer. Transendothelial elec-
trical resistance (TER) was measured in response to the EC barrier disruptive agent LPS using an electrical cell 
substrate impedance sensing system (ECIS; Applied Biophysics, Troy, NY) as we have previously described18,60. 
HPAEC transfected with siRNA specific to Moesin, Ezrin or Radixin were plated on gold microelectrodes. TER 
was measured 72 h later.
Evans Blue Dye (EBD) albumin extravasation into mouse lung. Adult male mice were anaesthetized 
using 150 mg/kg ketamine and acepromazine. LPS solution (1 mg/kg body weight) or 0.9% sterile saline was 
introduced intratracheally via a 20-gauge catheter. Animals were allowed to recover for 18 hours. Bronchoalveolar 
lavage fluid (BALF) and lungs were collected and stored at − 80 °C. Evans blue-labeled albumin dye (EBD) was 
injected into the tail vein 120 minutes before the termination of the experiment in order to assess vascular leak.
In vivo DNA delivery into mouse lung endothelium with JetPEI. In vivo gene delivery was per-
formed as we have previously described27. Briefly, wild type or D/N CS1β , C/A MYPT1, or phospho-null Moesin 
mutant in pcDNA 3.1 mammalian expression plasmids (40 μ g) or control empty plasmid pcDNA 3.1 (40 μ g) were 
incubated with glucose and jetPEI reagents, as per manufactures instruction for 15–30 minutes. Then, the cDNA/
jetPEI complexes were injected into 7–8 week old male mice via the tail vein27. At 72 hours post-injection, LPS 
(1 mg/kg) or sterile saline (0.9%) solution was instilled intratracheally (i.t.) via a 20-gauge catheter. Animals were 
allowed to recover for 18 hours. After the experiment, lungs were perfused with normal saline through the right 
ventricle, weighted and snap frozen in liquid nitrogen for further Western blot experiments. Bronchoalveolar 
lavage fluid (BALF) and lungs were collected and stored at −80 °C. EBD was measured in order to assess vascular 
leak.
Lung Histology. Lungs were perfused with PBS and immersed in 4% paraformaldehyde overnight. Sections 
(5 μ m) were cut from paraffin blocks and mounted on slides. Slides were deparafinized in xylene, and run through 
graded alcohol to distilled water. Slides were pretreated with Target Retrieval Solution (Dako, Carpinteria, CA) 
using a vegetable steamer and then were rinsed with distilled water. Lung sections were further used for myelop-
eroxidase staining.
Measurement of Myeloperoxidase (MPO) Activity. MPO assay kit was used for the staining as we 
have previously described27. Briefly, endogenous peroxidases were quenched with 0.3% H2O2 for 5 minutes fol-
lowed by distilled water for 2 minutes, and then washed with 1× PBS for 5 minutes. Slides were treated with 
Target Retrieval Solution, then incubated in Power Block Solution, rinsed in distilled water, placed in 1× PBS for 
5 minutes then incubated with anti-myeloperoxidase (MPO) antibody for 30 minutes at room temperature. The 
slides were rinsed twice in PBS then incubated with a secondary peroxidase-labeled polymer conjugated to goat 
anti-rabbit IgG for 30 minutes, and then finally rinsed again in PBS. Bound antibody was detected with diamin-
obenzidine (DAB + substrate kit). Hematoxylin was used as counter-stain.
Statistics. Values are expressed as mean ± SEM of at least 3 independent experiments. Analysis of variance 
(ANOVA) or Student’s t test was used, as appropriate. A P value of < 0.05 was considered statistically significant.
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